Related Experiment Video
Updated: Sep 30, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.9K
[How Myelodysplastic Syndrome is Diagnosed]
1Klinik für Medizinische Onkologie und Hämatologie, Kantonsspital St. Gallen.
Therapeutische Umschau. Revue Therapeutique
|March 16, 2022
Summary
Diagnosing myelodysplastic syndromes (MDS) relies on bone marrow morphology and cytogenetics. Advanced molecular techniques like next-generation sequencing (NGS) are increasingly vital for accurate MDS diagnosis and prognostication.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Diagnosis of myelodysplastic syndromes (MDS) traditionally relies on bone marrow morphology and conventional cytogenetics.
- Clinical history, physical examination, and peripheral blood smear analysis guide the initial differential diagnosis of cytopenic states.
Observation:
- Bone marrow cytology and histology are complementary for evaluating the myeloid compartment.
- Conventional metaphase cytogenetics is a crucial diagnostic tool.
- Flow cytometry, FISH, and SNP arrays enhance detection of genomic alterations.
Findings:
- Next-generation sequencing (NGS) comprehensively detects mutations in myeloid neoplasia genes.
- SF3B1 mutation detection is mandatory for MDS with ringed sideroblasts (>5%).
- NGS is expanding its role in MDS diagnostics and prognostication.
Implications:
- Comprehensive myeloid NGS panels are expected for standardized diagnostic work-up.
- NGS aids in refined prognostication and identification of druggable targets.
- Individualized monitoring of minimal residual disease post-transplant using NGS is anticipated.
